|
1
|
Bose P and Bandyopadhyay S: A
comprehensive assessment and classification of acute lymphocytic
leukemia. Math Comput Appl. 29:452024.
|
|
2
|
Sekeres MA, Guyatt G, Abel G, Alibhai S,
Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, et
al: American Society of Hematology 2020 guidelines for treating
newly diagnosed acute myeloid leukemia in older adults. Blood Adv.
4:3528–3549. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tirado HA, Balasundaram N, Laaouimir L,
Erdem A and van Gastel N: Metabolic crosstalk between stromal and
malignant cells in the bone marrow niche. Bone Rep. 18:1016692023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaszuba CM, Rodems BJ, Sharma S, Franco
EI, Ashton JM, Calvi LM and Bajaj J: Identifying bone marrow
microenvironmental populations in myelodysplastic Syndrome and
acute myeloid leukemia. J Vis Exp. Nov 10–2023.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye B, Sheng Y, Zhang M, Hu Y and Huang H:
Early detection and intervention of clonal hematopoiesis for
preventing hematological malignancies. Cancer Lett. 538:2156912022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coombs CC, Zehir A, Devlin S, Zehir A,
Devlin S, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, et
al: Mutational analysis of clonal hematopoiesis in solid tumor
patients Illustrates the critical role of systemic anti-cancer
therapies in the evolution of somatic leukemia disease alleles.
Blood. 128:372016. View Article : Google Scholar
|
|
7
|
Stengel A, Baer C, Walter W, Meggendorfer
M, Kern W, Haferlach T and Haferlach C: Mutational patterns and
their correlation to CHIP-related mutations and age in
hematological malignancies. Blood Adv. 5:4426–4434. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shiozawa Y, Havens AM, Pienta KJ and
Taichman RS: The bone marrow niche: Habitat to hematopoietic and
mesenchymal stem cells, and unwitting host to molecular parasites.
Leukemia. 22:941–950. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chowdhury MM: Stem cell in cancer disease
cure vs cause. 2022, https://dspace.bracu.ac.bd/xmlui/bitstream/handle/10361/17759/18146041_PHR.pdf?sequence=1.
|
|
10
|
Hoffman R: Progress in the development of
systems for in vitro expansion of human hematopoietic stem cells.
Curr Opin Hematol. 6:184–191. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Landau DA, Carter SL, Getz G and Wu CJ:
Clonal evolution in hematological malignancies and therapeutic
implications. Leukemia. 28:34–43. 2014. View Article : Google Scholar
|
|
12
|
Wang X, Huang S and Chen JL: Understanding
of leukemic stem cells and their clinical implications. Mol Cancer.
16:22017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Komarova NL, Burger JA and Wodarz D:
Evolution of ibrutinib resistance in chronic lymphocytic leukemia
(CLL). Proc Natl Acad Sci USA. 111:13906–13911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimony S, Stahl M and Stone RM: Acute
myeloid leukemia: 2023 update on diagnosis, risk-stratification,
and management. Am J Hematol. 98:502–526. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Am J Hematol. 93:442–459. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miranda-Filho A, Piñeros M, Ferlay J,
Soerjomataram I, Monnereau A and Bray F: Epidemiological patterns
of leukaemia in 184 countries: A population-based study. Lancet
Haematol. 5:e14–e24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin K, Jia H, Cao M, Xu T, Chen Z, Song X,
Miao Y, Yao T, Dong C, Shao J, et al: Epidemiological
characteristics of leukemia in China, 2005-2017: A log-linear
regression and age-period-cohort analysis. BMC Public Health.
23:16472023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT,
Alleman CJ, Hensen M, Skikne B and Smith BD: Economic burden
associated with acute myeloid leukemia treatment. Expert Rev
Hematol. 9:79–89. 2016. View Article : Google Scholar
|
|
19
|
Arber DA, Campo E and Jaffe ES: Advances
in the classification of myeloid and lymphoid neoplasms. Virchows
Arch. 482:1–9. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Al-Bayati A, Al-Bayti A and Husain V: A
short review about chronic myeloid leukemia. J Life Bio Sci Res.
4:15–19. 2023. View Article : Google Scholar
|
|
21
|
Sell S: Leukemia: Stem cells, maturation
arrest, and differentiation therapy. Stem Cell Rev. 1:197–206.
2005. View Article : Google Scholar
|
|
22
|
Cheng Y, Luo H and Kharas MG: Rubbing out
leukemia stem cells by erasing the eraser. Cell Stem Cell. 27:3–5.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kassahun W, Tesfaye G, Bimerew LG, Fufa D,
Adissu W and Yemane T: Prevalence of Leukemia and Associated
Factors among Patients with Abnormal Hematological Parameters in
Jimma Medical Center, Southwest Ethiopia: A Cross-Sectional Study.
Adv Hematol. 2020:1–7. 2020. View Article : Google Scholar
|
|
24
|
Jahic A, Iljazovic E, Hasic S, Arnautovic
AC, Sabitovic D, Mesanovic S, Sahovic H and Simendic V: Prognostic
Parameters of Acute Myeloid Leukaemia at Presentation. Med Arch.
71:20–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Luo XQ, Zhang P, Huang LB, Zheng
YS, Wu J, Zhou H, Qu LH, Xu L and Chen YQ: MicroRNA patterns
associated with clinical prognostic parameters and CNS relapse
prediction in pediatric acute leukemia. PLoS One. 4:e78262009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kardum-Skelin I, Planinc-Peraica A,
Ostojić Kolonić S, Radić-Kristo D, Milas M, Vrhovac R, Sustercić D,
Minigo H and Jaksić B: Clinical and laboratory prognostic
parameters for leukemic types of chronic lymphoproliferative
diseases. Acta Med Croatica. 62:351–364. 2008.In Croatian.
|
|
27
|
Othieno-Abinya NA, Mwanda WO, Maina MD,
Odhiambo AO, Mwanzi SA and Oyiro PO: Haematological parameters in
chronic myeloid leukaemia as determinants of clinical
manifestations in this disease. J Clin Oncol. 34:e185292016.
View Article : Google Scholar
|
|
28
|
Spiers AS: Management of the chronic
leukemias: Special considerations in the elderly patient. part II:
Chronic granulocytic leukemia. Hematology. 6:357–380. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sharma K, Puniyani RR, Bhat SV, Advani SH,
Hegde U and Rao S: Blood viscosity parameter correlation with types
of leukemia. Physiol Chem Phys Med NMR. 24:159–164. 1992.PubMed/NCBI
|
|
30
|
Germing U, Strupp C, Aivado M and
Gattermann N: New prognostic parameters for chronic myelomonocytic
leukemia? Blood. 100:731–732; author reply 732-3. 2002. View Article : Google Scholar
|
|
31
|
Tonorezos ES, Robien K, Eshelman-Kent D,
Moskowitz CS, Church TS, Ross R and Oeffinger KC: Contribution of
diet and physical activity to metabolic parameters among survivors
of childhood leukemia. Cancer Causes Control. 24:313–321. 2013.
View Article : Google Scholar :
|
|
32
|
Haferlach C, Dicker F, Weiss T, Schnittger
S, Beck C, Grote-Metke A, Oruzio D, Kern W and Haferlach T: Toward
a comprehensive prognostic scoring system in chronic lymphocytic
leukemia based on a combination of genetic parameters. Genes
Chromosomes Cancer. 49:851–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jaeger BA, Tauer JT, Ulmer A, Kuhlisch E,
Roth HJ and Suttorp M: Changes in bone metabolic parameters in
children with chronic myeloid leukemia on imatinib treatment. Med
Sci Monit. 18:CR721–CR728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Letestu R, Lévy V, Eclache V,
Baran-Marszak F, Vaur D, Naguib D, Schischmanoff O, Katsahian S,
Nguyen-Khac F, Davi F, et al: Prognosis of Binet stage A chronic
lymphocytic leukemia patients: the strength of routine parameters.
Blood. 116:4588–4590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Negrini M, Cutrona G, Bassi C, Fabris S,
Zagatti B, Colombo M, Ferracin M, D'Abundo L, Saccenti E, Matis S,
et al: microRNA ome expression in chronic lymphocytic leukemia:
Comparison with Normal B-cell subsets and correlations with
prognostic and clinical parameters. Clin Cancer Res. 20:4141–4153.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rigolin GM, Cibien F, Martinelli S,
Formigaro L, Rizzotto L, Tammiso E, Saccenti E, Bardi A, Cavazzini
F, Ciccone M, et al: Chromosome aberrations detected by
conventional karyotyping using novel mitogens in chronic
lymphocytic leukemia with 'normal' FISH: Correlations with
clinicobiologic parameters. Blood. 119:2310–2313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Babusikova O, Stevulova L and Fajtova M:
Immunophenotyping parameters as prognostic factors in T-acute
leukemia patients. Neoplasma. 56:508–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Joncourt F, Oberlischraummli AE, Stadler
M, Buser K, Franscini L, Fey MF and Cerny T: Patterns of Drug
Resistance Parameters in Adult Leukemia. Leuk Lymphoma. 17:101–109.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baumgartner A, Zueger N, Bargetzi A,
Medinger M, Passweg JR, Stanga Z, Mueller B, Bargetzi M and Schuetz
P: Association of nutritional parameters with clinical outcomes in
patients with acute myeloid leukemia undergoing haematopoietic stem
cell transplantation. Ann Nutr Metab. 69:89–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sillaber C, Mayerhofer M, Agis H, Sagaster
V, Mannhalter C, Sperr WR, Geissler K and Valent P: Chronic myeloid
leukemia: Pathophysiology, diagnostic parameters, and current
treatment concepts. Wien Klin Wochenschr. 115:485–504. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zittoun R, Cadiou M, Bayle C, Suciu S,
Solbu G and Hayat M: Prognostic value of cytologic parameters in
acute myelogenous leukemia. Cancer. 53:1526–1532. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Piard C, Bressolle F, Fakhoury M, Zhang D,
Yacouben K, Rieutord A and Jacqz-Aigrain E: A limited sampling
strategy to estimate individual pharmacokinetic parameters of
methotrexate in children with acute lymphoblastic leukemia. Cancer
Chemother Pharmacol. 60:609–620. 2006. View Article : Google Scholar
|
|
43
|
Halonen P, Mattila J, Suominen P, Ruuska
T, Salo MK and Mäkipernaa A: Iron overload in children who are
treated for acute lymphoblastic leukemia estimated by liver
siderosis and serum iron parameters. Pediatrics. 111:91–96. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Prabhu M, Kochupillai V, Sharma S,
Ramachandran P, Sundaram KR, Bijlani L and Ahuja RK: Prognostic
assessment of various parameters in chronic myeloid leukemia.
Cancer. 58:1357–1360. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shinawi T, Hill V, Dagklis A, Baliakas P,
Stamatopoulos K, Agathanggelou A, Stankovic T, Maher ER, Ghia P and
Latif F: KIBRAgene methylation is associated with unfavorable
biological prognostic parameters in chronic lymphocytic leukemia.
Epigenetics. 7:211–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Royer-Pokora B, Beug H, Claviez M,
Winkhardt HJ, Friis RR and Graf T: Transformation parameters in
chicken fibroblasts transformed by AEV and MC29 avian leukemia
viruses. Cell. 13:751–760. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Oliveira GB, Pereira FG, Metze K and
Lorand-Metze I: Spontaneous apoptosis in chronic lymphocytic
leukemia and its relationship to clinical and cell kinetic
parameters. Cytometry. 46:329–335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hofmann-Lehmann R, Holznagel E, Ossent P
and Lutz H: Parameters of disease progression in long-term
experimental feline retrovirus (feline immunodeficiency virus and
feline leukemia virus) infections: hematology, clinical chemistry,
and lymphocyte subsets. Clin Diagn Lab Immunol. 4:33–42. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chiaretti S, Marinelli M, Del Giudice I,
Bonina S, Piciocchi A, Messina M, Vignetti M, Rossi D, Di Maio V,
Mauro FR, et al: NOTCH1, SF3B1, BIRC3andTP53mutations in patients
with chronic lymphocytic leukemia undergoing first-line treatment:
correlation with biological parameters and response to treatment.
Leuk Lymphoma. 55:2785–2792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li J, Zheng R, Niu J, Song X, Wu W, Fan R
and Gong T: Correlation of intravoxel incoherent motion parameters
and histological characteristics from infiltrated marrow in
patients with acute leukemia. J Magn Reson Imaging. 51:1720–1726.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dhasmana R, Prakash A, Gupta N and Verma
SK: Ocular manifestations in leukemia and myeloproliferative
disorders and their association with hematological parameters. Ann
Afr Med. 15:97–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Omer SH, AA K, IM O, OH M, HN A and Elamin
BK: Prevalence of the different FAB sub type of Acute Myeloid
Leukemia related to hematological parameters in Sudanese. J Hematol
Blood Disord. 3:1022017. View Article : Google Scholar
|
|
53
|
Heintel D, Schwarzinger I,
Chizzali-Bonfadin C, Thalhammer R, Schwarzmeier J, Fritzer-Szekeres
M, Weltermann A, Simonitsch I, Lechner K and Jaeger U: Association
of CD38 antigen expression with other prognostic parameters in
early stages of chronic lymphocytic leukemia. Leuk Lymphoma.
42:1315–1321. 2001. View Article : Google Scholar
|
|
54
|
Molica S, Cutrona G, Vitelli G, Mirabelli
R, Molica M, Digiesi G, Ribatti D, Ferrarini M and Vacca A: Markers
of increased angiogenesis and their correlation with biological
parameters identifying high-risk patients in early B-cell chronic
lymphocytic leukemia. Leuk Res. 31:1575–1578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Levine PH, Merrill DA, Bethlenfalvay NC,
Dabich L, Stevens DA and Waggoner DE: A longitudinal comparison of
antibodies to epstein-barr virus and clinical parameters in chronic
lymphocytic leukemia and chronic myelocytic leukemia. Blood.
38:479–484. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Martell RE, Peterson BL, Cohen HJ, Petros
WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA,
et al: Analysis of age, estimated creatinine clearance and
pretreatment hematologic parameters as predictors of fludarabine
toxicity in patients treated for chronic lymphocytic leukemia: A
CALGB (9011) coordinated intergroup study. Cancer Chemother
Pharmacol. 50:37–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bergmann MA, Eichhorst BF, Busch R, Adorf
D, Stilgenbauer S, Eckart MJ, Wendtner CM and Hallek M; GCLLSG:
Prospective Evaluation of Prognostic Parameters in Early Stage
Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of
the German CLL Study Group (GCLLSG). Blood. 110:6252007. View Article : Google Scholar
|
|
58
|
Sinisalo M, Aittoniemi J, Koski T, Tobin
G, Thunberg U, Sundström C, Rosenquist R, Käyhty H and Vilpo J:
Similar Humoral Immunity Parameters in Chronic Lymphocytic Leukemia
Patients Independent of VH Gene Mutation Status. Leuk Lymphoma.
45:2451–2454. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Browman G, Goldberg J, Gottlieb AJ,
Preisler HD, Azarnia N, Priore RL, Brennan JK, Vogler WR, Winton
EF, Miller KB, et al: The clonogenic assay as a reproducible in
vitro system to study predictive parameters of treatment outcome in
acute nonlymphoblastic leukemia. Am J Hematol. 15:227–235. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wieser R, Scheideler M, Hackl H, Engelmann
M, Schneckenleithner C, Hiden K, Papak C, Trajanoski Z, Sill H and
Fonatsch C: microRNAs in acute myeloid leukemia: Expression
patterns, correlations with genetic and clinical parameters, and
prognostic significance. Genes Chromosomes Cancer. 49:193–203.
2010. View Article : Google Scholar
|
|
61
|
Valet G, Repp R, Link H, Ehninger A and
Gramatzki MM; SHG-AML study group: Pretherapeutic identification of
high-risk acute myeloid leukemia (AML) patients from
immunophenotypic, cytogenetic, and clinical parameters. Cytometry B
Clin Cytom. 53:4–10. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Valent P, Agis H, Sperr W, Sillaber C and
Horny HP: Diagnostic and prognostic value of new biochemical and
immunohistochemical parameters in chronic myeloid leukemia. Leuk
Lymphoma. 49:635–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zimm S, Reaman G, Murphy RF and Poplack
DG: Biochemical parameters of mercaptopurine activity in patients
with acute lymphoblastic leukemia. Cancer Res. 46:1495–1498.
1986.PubMed/NCBI
|
|
64
|
Yang JH, Kim Y, Lim J, Kim M, Oh EJ, Lee
HK, Park YJ, Min WS, Cho B, Lee K and Han K: Determination of acute
leukemia lineage with new morphologic parameters available in the
complete blood cell count. Ann Clin Lab Sci. 44:19–26.
2014.PubMed/NCBI
|
|
65
|
Olson KC, Moosic KB, Jones MK, Larkin PMK,
Olson TL, Toro MF, Fox TE, Feith DJ and Loughran TP Jr: Large
granular lymphocyte leukemia serum and corresponding hematological
parameters reveal unique cytokine and sphingolipid biomarkers and
associations with STAT3 mutations. Cancer Med. 9:6533–6549. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Srinivasan S, Cui H, Gao Z, Liu M, Lu S,
Mkandawire W, Narykov O, Sun M and Korkin D: Structural Genomics of
SARS-CoV-2 indicates evolutionary conserved functional regions of
viral proteins. Viruses. 12:3602020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hallek M: Chronic lymphocytic leukemia:
2020 update on diagnosis, risk stratification and treatment. Am J
Hematol. 94:1266–1287. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Feller N, van der Pol MA, van Stijn A,
Weijers GW, Westra AH, Evertse BW, Ossenkoppele GJ and Schuurhuis
GJ: MRD parameters using immunophenotypic detection methods are
highly reliable in predicting survival in acute myeloid leukaemia.
Leukemia. 18:1380–1390. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mohammadi Kanesbi M, Jarahi L and Keramati
MR: Blood parameters in treatment with arsenic trioxide in acute
promyelocytic leukemia: A systematic review. Int J Hematol Oncol
Stem Cell Res. 14:130–139. 2020.PubMed/NCBI
|
|
70
|
Al-Bayaa IM, Al-Rubaie HA and Al-Shammari
HH: Evaluation of hepatocyte growth factor in iraqi patients with
acute myeloid leukemia: Its correlation with clinical parameters
and response to induction therapy. Open Access Maced J Med Sci.
8:49–53. 2020. View Article : Google Scholar
|
|
71
|
Khazaal MS, Hamdan FB and Al-Mayah QS:
Association of BCR/ABL transcript variants with different blood
parameters and demographic features in Iraqi chronic myeloid
leukemia patients. Mol Genet Genomic Med. 7:e8092019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ogasawara A, Matsushita H, Tanaka Y,
Shirasugi Y, Ando K, Asai S and Miyachi H: A simple screening
method for the diagnosis of chronic myeloid leukemia using the
parameters of a complete blood count and differentials. Clin Chim
Acta. 489:249–253. 2019. View Article : Google Scholar
|
|
73
|
Michailov Y, Lunenfeld E, Kapilushnik J,
Friedler S, Meese E and Huleihel M: Acute myeloid leukemia affects
mouse sperm parameters, spontaneous acrosome reaction, and
fertility capacity. Int J Mol Sci. 20:2192019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Virk H, Varma N, Naseem S, Bihana I and
Sukhachev D: Utility of cell population data (VCS parameters) as a
rapid screening tool for Acute Myeloid Leukemia (AML) in
resource-constrained laboratories. J Clin Lab Anal. 33:e226792019.
View Article : Google Scholar
|
|
75
|
Vigón L, Luna A, Galán M, Rodríguez-Mora
S, Fuertes D, Mateos E, Piris-Villaespesa M, Bautista G, San José
E, Rivera-Torres J, et al: Identification of immunological
parameters as predictive biomarkers of relapse in patients with
chronic myeloid leukemia on treatment-free remission. J Clin Med.
10:422020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mahmood R, Khan SA, Altaf C, Malik HS and
Khadim MT: Clinicohematological parameters and outcomes in a cohort
of chronic lymphocytic leukemia patients with Deletion 17p from
Pakistan. Blood Res. 53:276–280. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kim H, Ahn SI, Jhoo JW and Kim GY:
Comparison of Allergic Parameters between Whey Protein Concentrate
and Its Hydrolysate in Rat Basophilic Leukemia (RBL)-2H3 Cells.
Korean J Food Sci Anim Resour. 38:780–793. 2018.PubMed/NCBI
|
|
78
|
Schillinger F, Sourdeau E, Boubaya M,
Baseggio L, Clauser S, Cornet E, Debord C, Defour JP, Dubois F,
Eveillard M, et al: A new approach for diagnosing chronic
myelomonocytic leukemia using structural parameters of Sysmex XN™
analyzers in routine laboratory practice. Scand J Clin Lab Invest.
78:159–164. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Khan MI: Acute Myeloid Leukemia: Pattern
of clinical and hematological parameters in a tertiary care centre.
Int J Pathol. 11:58–63. 2018.
|
|
80
|
Podszywalow-Bartnicka P, Kominek A,
Wolczyk M, Kolba MD, Swatler J and Piwocka K: Characteristics of
live parameters of the HS-5 human bone marrow stromal cell line
cocultured with the leukemia cells in hypoxia, for the studies of
leukemia-stroma cross-talk. Cytometry A. 93:929–940. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Nägele V, Kratzer A, Zugmaier G, Holland
C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A and
Klinger M: Changes in clinical laboratory parameters and
pharmacodynamic markers in response to blinatumomab treatment of
patients with relapsed/refractory ALL. Exp Hematol Oncol. 6:142017.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Lekovic D, Gotic M, Milic N, Zivojinovic
B, Jovanovic J, Colovic N, Milosevic V and Bogdanovic A: Predictive
parameters for imatinib failure in patients with chronic myeloid
leukemia. Hematology. 22:460–466. 2017.PubMed/NCBI
|
|
83
|
Burhan I: Estimation Of Alpha-Fetoprotein
(AFP) and some of biochemical parameters in leukemia patients.
World J Pharm Pharma Sci. 5:2275–2283. 2017.
|
|
84
|
Elzubeir MA, Angi A, Rahoum H, Ismail IA,
Mohammed ME, Yousef MM, Khair SM, Namarq Alaaldeen SA, Osman RAM,
Duaa Ali AA, et al: Prognostic Significance of Immune Function
Parameters (CD4, CD8 and CD4/CD8 ratio) in Sudanese Patients with
Chronic Lymphocytic leukemia. Int J Multidiscip Curr Res.
4:7650–653. 2016.
|
|
85
|
Wenn K, Tomala L, Wilop S, Vankann L,
Hasenbank C, Frank O, Hochhaus A, Giles FJ, Lange T, Müller MC, et
al: Telomere length at diagnosis of chronic phase chronic myeloid
leukemia (CML-CP) identifies a subgroup with favourable prognostic
parameters and molecular response according to the ELN criteria
after 12 months of treatment with nilotinib. Leukemia.
29:2402–2404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Trendowski M, Wong V, Zoino JN, Christen
TD, Gadeberg L, Sansky M and Fondy TP: Preferential enlargement of
leukemia cells using cytoskeletal-directed agents and cell cycle
growth control parameters to induce sensitivity to low frequency
ultrasound. Cancer Lett. 360:160–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Huang Z, Liu WJ, Guo QL and Liu CY:
Platelet parameters and expression of platelet membrane
glycoprotein in childhood acute lymphoblastic leukemia. Genet Mol
Res. 14:16074–16089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rabizadeh E, Pickholtz I, Barak M, Isakov
E, Zimra Y and Froom P: Acute leukemia detection rate by automated
blood count parameters and peripheral smear review. Int J Lab
Hematol. 37:44–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Koltan S, Debski R, Koltan A, Grzesk E,
Tejza B, Eljaszewicz A, Gackowska L, Kubicka M, Kolodziej B,
Kurylo-Rafinska B, et al: Phenotype of NK cells determined on the
basis of selected immunological parameters in children treated due
to acute lymphoblastic leukemia. Medicine (Baltimore).
94:e23692015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Aljamaan K, Aljumah TK, Aloraibi S, Absar
M and Iqbal Z: Low Frequency of ETV6-RUNX1 (t 12; 21) in Saudi
Arabian pediatric acute lymphoblastic leukemia patients:
Association with clinical parameters and early remission. Asian Pac
J Cancer Prev. 16:7523–7527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rafiq N, Iqbal T, Shahid M and Muhammad F:
Hematological and Biochemical Parameters in Pakistani Chronic
Lymphoblastic Leukemia Patients. Pak J Life Soc Sci. 12:16–19.
2014.
|
|
92
|
Pietras W, Chaber R, Pela H, Trybucka K
and Chybicka A: The recovery of immune system parameters in
children following lymphoblastic leukemia therapy-preliminary
report. Adv Clin Exp Med. 23:97–102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Deschler B, Ihorst G, Platzbecker U,
Germing U, März E, de Figuerido M, Fritzsche K, Haas P, Salih HR,
Giagounidis A, et al: Parameters detected by geriatric and quality
of life assessment in 195 older patients with myelodysplastic
syndromes and acute myeloid leukemia are highly predictive for
outcome. Haematologica. 98:208–216. 2013. View Article : Google Scholar :
|
|
94
|
Mauro MJ, Cortes JE, Kim DW, Pinilla-Ibarz
J, Coutre PI, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury
HJ, et al: Multivariate Analyses of the Clinical and Molecular
Parameters Associated with Efficacy and Safety in Patients with
Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive
Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in
the PACE Trial. Blood. 120:37472012. View Article : Google Scholar
|
|
95
|
Dong HJ, Miao KR, Qiao C, Zhuang Y, Shen
WY, Hong M, Fan L, Liu P, Xu W and Li JY: Polymorphisms and
haplotypes in multidrug resistance 1 gene are not associated with
chronic lymphocytic leukemia susceptibility and prognostic
parameters of chronic lymphocytic leukemia in Chinese population.
Leuk Lymphoma. 52:1003–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Onida F, Kantarjian HM, Smith TL, Ball G,
Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI and Beran M:
Prognostic factors and scoring systems in chronic myelomonocytic
leukemia: A retrospective analysis of 213 patients. Blood.
99:840–849. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sagatys EM and Zhang L: Clinical and
laboratory prognostic indicators in chronic lymphocytic leukemia.
Cancer Control. 19:18–25. 2012. View Article : Google Scholar
|
|
98
|
Jinlong S, Lin F, Yonghui L, Li Y and
Weidong W: Identification of let-7a-2-3p or/and miR-188-5p as
prognostic biomarkers in cytogenetically normal acute myeloid
leukemia. PLoS One. 10:e01180992015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Marcucci G, Mrózek K, Radmacher MD, Garzon
R and Bloomfield CD: The prognostic and functional role of
microRNAs in acute myeloid leukemia. Blood. 117:1121–1129. 2011.
View Article : Google Scholar :
|
|
100
|
Labib HA, Elantouny NG, Ibrahim NF and
Alnagar AA: Upregulation of microRNA-21 is a poor prognostic marker
in patients with childhood B cell acute lymphoblastic leukemia.
Hematology. 22:392–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Neaga A, Bagacean C, Tempescul A, Jimbu L,
Mesaros O, Blag C, Tomuleasa C, Bocsan C, Gaman M and Zdrenghea M:
MicroRNAs associated with a good prognosis of acute myeloid
leukemia and their effect on macrophage polarization. Front
Immunol. 11:5829152021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ciesielska M, Orzechowska B, Gamian A and
Kazanowska B: Epidemiology of childhood acute leukemias. Postep Hig
Med Dosw. 78:22–36. 2024.In Polish. View Article : Google Scholar
|
|
103
|
Mari JF, de Miranda ÉJFP, Mendes-Correa
MC, Chow FC and Vidal JE: Progressive multifocal
leukoencephalopathy and spectrum of predisposing conditions: A
20-year retrospective cohort study in a tertiary center in São
Paulo, Brazil. Neurol Sci. Jul 15–2024.Epub ahead of print.
View Article : Google Scholar
|
|
104
|
Aureli A, Marziani B, Venditti A,
Sconocchia T and Sconocchia G: Acute Lymphoblastic Leukemia
Immunotherapy Treatment: Now, Next, and Beyond. Cancers (Basel).
15:33462023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Giannakaki AG, Giannakaki MN, Oikonomou E,
Nikolettos K, Bothou A, Kotanidou S, Andreou S, Kritsotaki N,
Nalmpanti T, Spanoudakis E, et al: Leukemia in pregnancy: Diagnosis
and therapeutic approach (Review). Mol Clin Oncol. 21:792024.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
van der Straten L, Levin MD, Dinnessen
MAW, Visser O, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP
and Dinmohamed AG: Risk of second primary malignancies in patients
with chronic lymphocytic leukemia: A population-based study in the
Netherlands, 1989-2019. Blood Cancer J. 13:152023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Jain M, Rai A, Kushwaha R, Yadav G, Mishra
S, Verma SP, Singh US, Tripathi AK and Kumar A: A cross sectional
study on T Cells and Subsets in Chronic Lymphocytic Leukemia and
their Association with Clinical Phenotype. Indian J Hematol Blood
Transfus. 37:563–568. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Qurat Ul Ain, Akbar S, Gull S, Hussain M
and Ayesha N: Leukemia detection using machine and deep learning
through microscopic images-A review. Studies in Big Data. Jul
7–2022.Epub ahead of print.
|
|
109
|
Alcazer V, Le Meur G, Roccon M, Barriere
S, Le Calvez B, Badaoui B, Spaeth A, Kosmider O, Freynet N,
Eveillard M, et al: Evaluation of a machine-learning model based on
laboratory parameters for the prediction of acute leukaemia
subtypes: A multicentre model development and validation study in
France. Lancet Digit Health. 6:e323–e333. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Vineela M, Reddy GDS, Karthik G,
Muthukumaran N and Al Deen SH: Classification of Leukemia White
Blood Cell Cancer. In: 2024 International Conference on Inventive
Computation Technologies (ICICT); pp. 1233–1236. 2024
|
|
111
|
Papadakis S, Liapis I, Papadhimitriou SI,
Spanoudakis E, Kotsianidis I and Liapis K: Approach to acute
myeloid leukemia with increased eosinophils and basophils. J Clin
Med. 13:8762024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ahmed MR and Anis M: In vitro regeneration
and the antioxidant enzymatic system on acclimatization of
micropropagated Vitex trifolia L. Agroforest Syst. 88:437–447.
2014. View Article : Google Scholar
|
|
113
|
Li H, Xu C, Xin B, Zheng C, Zhao Y, Hao K,
Wang Q, Wahl RL, Wang X and Zhou Y: 18F-FDG PET/CT radiomic
analysis with machine learning for identifying bone marrow
involvement in the patients with suspected relapsed acute leukemia.
Theranostics. 9:4730–4739. 2019. View Article : Google Scholar :
|
|
114
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017. View Article : Google Scholar :
|
|
115
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J: WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours;
2017
|
|
116
|
Tallman MS, Wang ES, Altman JK, Appelbaum
FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M,
et al: Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical
Practice Guidelines in Oncology. J Natl Compr Canc Netw.
17:721–749. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Jondreville L, Krzisch D, Chapiro E and
Nguyen-Khac F: The complex karyotype and chronic lymphocytic
leukemia: prognostic value and diagnostic recommendations. Am J
Hematol. 95:1361–1367. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Andreieva SV, Korets KV, Tsyapka OM and
Skorokhod IM: Comparative Characteristics of Abnormal Karyotypes in
Secondary Acute Leukemia. Cytol Genet. 58:292–299. 2024. View Article : Google Scholar
|
|
119
|
Olde Nordkamp L, Mellink C, van der Schoot
E and van den Berg H: Karyotyping FISH, and PCR in acute
lymphoblastic leukemia: competing or complementary diagnostics? J
Pediatr Hematol Oncol. 31:930–935. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Camuset M, Le Calvez B, Theisen O, Godon
C, Grain A, Thomas C, Couec ML, Béné MC, Rialland F and Eveillard
M: Added value of molecular karyotype in childhood acute
lymphoblastic leukemia. Cancer Innov. 2:513–523. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kibler CE and Chabot-Richards DS:
Molecular Pathology of Leukemia. Molecular Surgical Pathology.
Cheng L, Netto GJ and Eble JN: Springer International Publishing;
Cham: pp. 681–709. 2023, View Article : Google Scholar
|
|
122
|
Bayani J and Squire JA: Preparation of
cytogenetic specimens from tissue samples. Curr Protoc Cell Biol.
Chapter 22: Unit 22.2. 2004. View Article : Google Scholar
|
|
123
|
Stölzel F, Mohr B, Kramer M, Oelschlägel
U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K,
Stuhlmann R, et al: Karyotype complexity and prognosis in acute
myeloid leukemia. Blood Cancer J. 6:e3862016. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kiefer Y, Schulte C, Tiemann M and
Bullerdiek J: Chronic lymphocytic leukemia-associated chromosomal
abnormalities and miRNA deregulation. Appl Clin Genet. 5:21–28.
2012.PubMed/NCBI
|
|
125
|
Alhourani E, Rincic M, Othman MA, Pohle B,
Schlie C, Glaser A and Liehr T: Comprehensive chronic lymphocytic
leukemia diagnostics by combined multiplex ligation dependent probe
amplification (MLPA) and interphase fluorescence in situ
hybridization (iFISH). Mol Cytogenet. 7:792014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Han X, Jin C, Zheng G, Li Y, Wang Y, Zhang
E, Zhu H and Cai Z: Acute myeloid leukemia with CPSF6-RARG fusion
resembling acute promyelocytic leukemia with extramedullary
infiltration. Ther Adv Hematol. 12:20406207209769842021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Gupta V, Shariff M, Bajwa R, Patel I,
Ayyad HA, Levitt MJ, Mencel PJ and Hossain MA: Acute myeloid
leukemia acquiring promyelocytic leukemia-retinoic acid receptor
alpha at relapse. World J Oncol. 10:153–156. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hochhaus A, Baccarani M, Silver RT,
Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE,
Deininger MW, Guilhot F, et al: European LeukemiaNet 2020
recommendations for treating chronic myeloid leukemia. Leukemia.
34:966–984. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Danylesko I, Jacoby E, Yerushalmi R,
Shem-Tov N, Besser MJ, Vernitsky H, Marcu-Malina V, Shimoni A,
Avigdor A and Nagler A: Remission of acute myeloid leukemia with
t(8;21) following CD19 CAR T-cells. Leukemia. 34:1939–1942. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Bellesi S, Schiaffini G, Contegiacomo A,
Maiolo E, Iacovelli C, Malafronte R, D'Innocenzo S, Alma E,
Bellisario F, Viscovo M, et al: Enhancing lymphoma diagnosis on
core needle biopsies: Integrating immunohistochemistry with flow
cytometry. Cytometry B Clin Cytom. Jun 14–2024.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Kurosawa S and Nakazato T:
Immunohistochemical differentiation of extramedullary acute myeloid
leukemia from blastic plasmacytoid dendritic cell neoplasm. Int J
Hematol. 120:391–393. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Hisada Y, Archibald SJ, Bansal K, Chen Y,
Dai C, Dwarampudi S, Balas N, Hageman L, Key NS, Bhatia S, et al:
Biomarkers of bleeding and venous thromboembolism in patients with
acute leukemia. J Thromb Haemost. 22:1984–1996. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
De Coninck S, De Smedt R, Lintermans B,
Reunes L, Kosasih HJ, Reekmans A, Brown LM, Van Roy N, Palhais B,
Roels J, et al: Targeting hyperactive platelet-derived growth
factor receptor-β signaling in T-cell acute lymphoblastic leukemia
and lymphoma. Haematologica. 109:1373–1384. 2024.
|
|
134
|
Elliott MA and Tefferi A: Chronic
neutrophilic leukemia: 2018 update on diagnosis, molecular genetics
and management. Am J Hematol. 93:578–587. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Fiala GJ and Minguet S: Caveolin-1: The
Unnoticed Player in TCR and BCR Signaling. Adv Immunol. 137:83–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Apostolopoulos A, Symeonidis A and Zoumbos
N: Prognostic significance of immune function parameters in
patients with chronic lymphocytic leukaemia. Eur J Haematol.
44:39–44. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Nardini G, Leopardi S and Bielli M:
Clinical Hematology in Reptilian Species. Vet Clin North Am Exot
Anim Pract. 16:1–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Oliveira ALCSL, Zerillo L, Cruz LJ,
Schomann T, Chan AB, de Carvalho TG, Souza SVP, Araújo AA, de
Geus-Oei LF and de Araújo Júnior RF: Maximizing the potency of
oxaliplatin coated nanoparticles with folic acid for modulating
tumor progression in colorectal cancer. Mater Sci Eng C Mater Biol
Appl. 120:1116782021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Belov L, Huang P, Barber N, Mulligan SP
and Christopherson RI: Identification of repertoires of surface
antigens on leukemias using an antibody microarray. Proteomics.
3:2147–2154. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Hömig-Hölzel C and Savola S: Multiplex
Ligation-dependent Probe Amplification (MLPA) in Tumor Diagnostics
and Prognostics. Diagn Mol Pathol. 21:189–206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ningombam A, Verma D, Kumar R, Singh J,
Ali MS, Pandey AK, Singh I, Bakhshi S, Sharma A, Pushpam D, et al:
Prognostic relevance of NPM1, CEBPA, and FLT3 mutations in
cytogenetically normal adult AML patients. Am J Blood Res.
13:28–43. 2023.PubMed/NCBI
|
|
142
|
Dietrich P, Gaza A, Wormser L, Fritz V,
Hellerbrand C and Bosserhoff AK: Neuroblastoma RAS Viral Oncogene
Homolog (NRAS) is a novel prognostic marker and contributes to
sorafenib resistance in hepatocellular carcinoma. Neoplasia.
21:257–268. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li S, Mason C and Melnick A: Genetic and
epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet
Dev. 36:100–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar
|
|
145
|
Menssen AJ and Walter MJ: Genetics of
progression from MDS to secondary leukemia. Blood. 136:50–60. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Bond J, Touzart A, Leprêtre S, Graux C,
Bargetzi M, Lhermitte L, Hypolite G, Leguay T, Hicheri Y, Guillerm
G, et al: DNMT3A mutation is associated with increased age and
adverse outcome in adult T-cell acute lymphoblastic leukemia.
Haematologica. 104:1617–1625. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Stone RM: The difficult problem of acute
myeloid leukemia in the older adult. CA Cancer J Clin. 52:363–371.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Appelbaum FR, Gundacker H, Head DR, Slovak
ML, Willman CL, Godwin JE, Anderson JE and Petersdorf SH: Age and
acute myeloid leukemia. Blood. 107:3481–3485. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Manescu P, Narayanan P, Bendkowski C, Elmi
M, Claveau R, Pawar V, Brown BJ, Shaw M, Rao A and Fernandez-Reyes
D: Detection of acute promyelocytic leukemia in peripheral blood
and bone marrow with annotation-free deep learning. Sci Rep.
13:25622023. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Verma D, Yadav R, Ahirwar R and Meena P:
Importance of bone marrow examination in cases of pancytopenia: A
morphological study in a tertiary care center. Asian J Med Sci.
15:202–205. 2024. View Article : Google Scholar
|
|
151
|
Rivera D, Cui W, Gao J, Peker D, Zhang QY,
Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, et al: Aleukemic
chronic myeloid leukemia without neutrophilia and thrombocytosis: A
Report From the BCR::ABL1 Pathology Group. Mod Pathol.
37:1004062024. View Article : Google Scholar
|
|
152
|
Terwilliger T and Abdul-Hay M: Acute
lymphoblastic leukemia: A comprehensive review and 2017 update.
Blood Cancer J. 7:e5772017. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Am J Hematol. 95:691–709. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Troussard X, Maître E and Cornet E: Hairy
cell leukemia 2022: Update on diagnosis, risk-stratification, and
treatment. Am J Hematol. 97:226–236. 2022. View Article : Google Scholar
|
|
155
|
Wood ME: Chapter 57-Oncologic Emergencies
(Including Hypercalcemia). Critical Care Secrets (Fifth Edition).
Parsons PE and Wiener-Kronish JP: Mosby; Philadelphia, PA: pp.
404–409. 2013, View Article : Google Scholar
|
|
156
|
Kang SH, Kim HK, Ham CK, Lee DS and Cho
HI: Comparison of four hematology analyzers, CELL-DYN Sapphire,
ADVIA 120, Coulter LH 750, and Sysmex XE-2100, in terms of clinical
usefulness. Int J Lab Hematol. 30:480–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
He G, Jiang Z, Xue S, Sun X and Wang W:
Expression of LDH and CEA in serum in the process of targeted
therapy of lung adenocarcinoma and the association between them and
prognosis. Oncol Lett. 17:4550–4556. 2019.PubMed/NCBI
|
|
158
|
Oliveira LC, Romano LG, Prado-Junior BP,
Covas DT, Rego EM and De Santis GC: Outcome of acute myeloid
leukemia patients with hyperleukocytosis in Brazil. Med Oncol.
27:1254–1259. 2010. View Article : Google Scholar
|
|
159
|
Zografos E, Zagouri F, Kalapanida D,
Zakopoulou R, Kyriazoglou A, Apostolidou K, Gazouli M and
Dimopoulos MA: Prognostic role of microRNAs in breast cancer: A
systematic review. Oncotarget. 10:7156–7178. 2019. View Article : Google Scholar
|
|
160
|
Davis-Dusenbery BN and Hata A: MicroRNA in
Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory
Pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar
|
|
161
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
162
|
Garzon R, Garofalo M, Martelli MP,
Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG,
Schnittger S, Haferlach T, et al: Distinctive microRNA signature of
acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Proc Natl Acad Sci USA. 105:3945–3950. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
164
|
Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly
MB, Wang Y, Qian Z, Jin J, Zhang Y, et al: MicroRNA expression
signatures accurately discriminate acute lymphoblastic leukemia
from acute myeloid leukemia. Proc Natl Acad Sci USA.
104:19971–19976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Marcucci G, Maharry K, Radmacher MD,
Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus
CD, Liu CG, et al: Prognostic significance of, and gene and
microRNA expression signatures associated with, CEBPA mutations in
cytogenetically normal acute myeloid leukemia with high-risk
molecular features: A Cancer and Leukemia Group B Study. J Clin
Oncol. 26:5078–5087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT,
Chen P, Wang Y, Yan M, Qian Z, et al: Distinct microRNA expression
profiles in acute myeloid leukemia with common translocations. Proc
Natl Acad Sci USA. 105:15535–15540. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Abbott BL, Rubnitz JE, Tong X, Srivastava
DK, Pui CH, Ribeiro RC and Razzouk BI: Clinical significance of
central nervous system involvement at diagnosis of pediatric acute
myeloid leukemia: A single institution's experience. Leukemia.
17:2090–2096. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Lin KI, Tam CS, Keating MJ, Wierda WG,
O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron
LL, et al: Relevance of the immunoglobulin VH somatic mutation
status in patients with chronic lymphocytic leukemia treated with
fludarabine, cyclophosphamide, and rituximab (FCR) or related
chemoimmunotherapy regimens. Blood. 113:3168–3171. 2009. View Article : Google Scholar
|
|
169
|
Rai KR, Sawitsky A, Cronkite EP, Chanana
AD, Levy RN and Pasternack BS: Clinical staging of chronic
lymphocytic leukemia. Blood. 46:219–234. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Binet JL, Auquier A, Dighiero G, Chastang
C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F,
et al: A new prognostic classification of chronic lymphocytic
leukemia derived from a multivariate survival analysis. Cancer.
48:198–206. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Muñoz L, Lasa A, Carricondo MT, Hernández
C, Ubeda J and Nomdedéu JF: Comparative analysis of ZAP-70
expression and Ig VH mutational status in B-cell chronic
lymphocytic leukemia. Cytometry B Clin Cytom. 72:96–102.
2006.PubMed/NCBI
|
|
172
|
Michels E, Vandesompele J, De Preter K,
Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques
B, Stallings RL, et al: ArrayCGH-based classification of
neuroblastoma into genomic subgroups. Genes Chromosomes Cancer.
46:1098–1108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Daver N, Schlenk RF, Russell NH and Levis
MJ: Targeting FLT3 mutations in AML: Review of current knowledge
and evidence. Leukemia. 33:299–312. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Sakaguchi M, Yamaguchi H, Najima Y, Usuki
K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, et al:
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation
in acute myeloid leukemia. Blood Adv. 2:2744–2754. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Kennedy VE and Smith CC: FLT3 mutations in
acute myeloid leukemia: key concepts and emerging controversies.
Front Oncol. 10:6128802020. View Article : Google Scholar
|
|
176
|
Basso G, Veltroni M, Valsecchi MG, Dworzak
MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera
G, et al: Risk of relapse of childhood acute lymphoblastic leukemia
is predicted by flow cytometric measurement of residual disease on
day 15 bone marrow. J Clin Oncol. 27:5168–5174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Bader P, Kreyenberg H, Henze GH, Eckert C,
Reising M, Willasch A, Barth A, Borkhardt A, Peters C,
Handgretinger R, et al: Prognostic value of minimal residual
disease quantification before allogeneic stem-cell transplantation
in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM
Study Group. J Clin Oncol. 27:377–384. 2009. View Article : Google Scholar
|
|
178
|
Jongen-Lavrencic M, Grob T, Hanekamp D,
Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ,
Gradowska PL, Meijer R, Cloos J, et al: Molecular Minimal Residual
Disease in Acute Myeloid Leukemia. N Engl J Med. 378:1189–1199.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Vosberg S and Greif PA: Clonal evolution
of acute myeloid leukemia from diagnosis to relapse. Genes
Chromosomes Cancer. 58:839–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Lussana F, Caprioli C, Stefanoni P, Pavoni
C, Spinelli O, Buklijas K, Michelato A, Borleri G, Algarotti A,
Micò C, et al: Molecular detection of minimal residual disease
before allogeneic stem cell transplantation predicts a high
incidence of early relapse in adult patients with NPM1 positive
acute myeloid leukemia. Cancers (Basel). 11:14552019. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Balatzenko G, Vundinti BR and Margarita G:
Correlation between the type of bcr-abl transcripts and blood cell
counts in chronic myeloid leukemia-a possible influence of mdr1
gene expression. Hematol Rep. 3:e32011. View Article : Google Scholar
|
|
182
|
Brinkmann U: Functional Polymorphisms of
the Human Multidrug Resistance (MDR1) Gene: Correlation with P
glycoprotein Expression and Activity in vivo. Novartis Found Symp.
243:207–10; discussion 207-212. 231-5. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Vendrik CP, Bergers JJ, De Jong WH and
Steerenberg PA: Resistance to cytostatic drugs at the cellular
level. Cancer Chemother Pharmacol. 29:413–429. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Vandyke K, Fitter S, Dewar AL, Hughes TP
and Zannettino ACW: Dysregulation of bone remodeling by imatinib
mesylate. Blood. 115:766–774. 2010. View Article : Google Scholar
|
|
185
|
Druker BJ, Guilhot F, O'Brien SG, Gathmann
I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM,
Stone RM, et al: Five-Year follow-up of patients receiving imatinib
for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Millot F, Baruchel A, Guilhot J, Petit A,
Leblanc T, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, et
al: Imatinib is effective in children with previously untreated
chronic myelogenous leukemia in early chronic phase: Results of the
French National Phase IV Trial. J Clin Oncol. 29:2827–2832. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Ebnöether M, Stentoft J, Ford J, Buhl L
and Gratwohl A: Cerebral oedema as a possible complication of
treatment with imatinib. Lancet. 359:1751–1752. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Mughal TI and Schrieber A: Principal
long-term adverse effects of imatinib in patients with chronic
myeloid leukemia in chronic phase. Biologics. 4:315–323. 2010.
|
|
189
|
Suttorp M and Millot F: Treatment of
pediatric chronic myeloid leukemia in the year 2010: Use of
tyrosine kinase inhibitors and stem-cell transplantation.
Hematology Am Soc Hematol Educ Program. 2010:368–376. 2010.
View Article : Google Scholar
|
